ClinicalTrials.Veeva

Menu

Are Mast Cells Involved in Autoinflammatory Diseases (INFLAMAST)

A

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Autoinflammatory Disease
Cryopyrin Associated Periodic Syndrome
Haploinsufficiency
TRAPS
MKD
FMF

Study type

Observational

Funder types

Other

Identifiers

NCT05292768
APHP210126

Details and patient eligibility

About

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.

Full description

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation and characterized by recurrent bouts of fever, frequently associated with digestive, articular or cutaneous symptoms, and sometimes ocular, auricular or neurologic inflammation. The most frequent monogenic AID is Familial Mediterranean fever (FMF).

Despite recent genetic progress AID pathophysiology is only partly understood, especially in the case of unclassified AID.

Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome (MCAS). In MCAS, patients have various symptoms including abdominal pain, bloating, pruritus, flush, anxiety, fatigue, among which some are similar to those seen in patients with AID. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).

Our hypothesis is that MC could be involved in AID pathophysiology,

In order to test this hypothesis, we plan to study :

  • clinical MC activation symptoms via a standardized clinical score
  • biological MC mediators : by measuring total serum tryptase and histamine in total blood, plasma and urine
  • MC infiltration on gastro-intestinal (GI) tract and cutaneous biopsies We will compare clinical MC activation score in AID patients to patients with mastocytosis, with other inflammatory diseases, and with healthy controls.

Enrollment

590 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients >18 years old with Auto-inflammatory diseases already followed up at the CeRéMAIA (french national reference center for autoinflamamtory diseases and AA amyloidosis) of Tenon hospital and included in the JIRcohorte
  • Healthy adult controls, age- and sex-matched with MAI patients, and controls with mastocytosis, an immuno-inflammatory disease.
  • Subject affiliated to or entitled to a social security scheme
  • Collection of the patient's or healthy control's non-opposition

Exclusion criteria

  • Subjects unable to answer questions or express themselves
  • Subjects who do not speak French
  • Subject deprived of liberty or under legal protection.

Trial design

590 participants in 6 patient groups

Patients with AID
Control patients with mastocytosis
Control patients with normal digestive biopsy
Control patients with renal biopsy
Control patients with inflammatory disease
Healthy control from healthcare workers

Trial contacts and locations

1

Loading...

Central trial contact

Nabiha Sbeih, MD; Sophie GEORGIN-LAVIALLE, PU-PH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems